In yet another hit to medication creator Wockhardt, US Food and Drug Administration (USFDA) has banned import of items fabricated at its Ankleshwar plant for rebelliousness of assembling standards.
The organization's Ankleshwar plant fabricates mass medications, the USFDA said in a notification on its site. The import alarm has been issued under 'Import Alert 66-40', which approves the wellbeing controller "detainment without physical examination of medications from firms which have not met drug GMPs".
As of now the organization's two plants at Chikalthana and Waluj have been banned from trading medications to the US by the US wellbeing controller. In November 2013, the USFDA had forced confinements on import of prescriptions delivered at the organization's Chikalthana plant at Aurangabad in Maharashtra.
Prior in May, the USFDA had likewise issued an import alarm on the organization's Waluj office which makes injectables and strong measurements. Wockhardt offers finished at Rs.1,015.60 on BSE, up 0.49% from the past close.